Loading…

Perrigo Co. PlcPRGOCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

World's largest maker of store-brand over-the-counter health and infant-formula products for retailers.

Momentum leader 94
Mkt cap
$2.35B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$34.9M
20-day average traded
Fwd P/E
6.7×
forward earnings
ROIC−WACC
-4.1 pp
WACC 6.8%
Hurdle
+13 pp
Req g minus delivered
Official | Implied
B+ / BB
agencies · bond market
Next earnings
103 days
1 Mar 2027
Close · USD$16.94
1D+7.5%
1W+2.4%
1M+4.8%
3M+23.6%
6M+51.8%
YTD+21.7%
1Y+24.9%
ATR %4.3%
Beta1.04
52w lowhigh0.8% off high

What Perrigo does

World's largest maker of store-brand over-the-counter health and infant-formula products for retailers.

Splits between store-brand products it makes for retailers' own labels in the US, where it competes on price and supply reliability, and its own branded consumer-health lines in Europe, built through the 2015 Omega Pharma purchase. It sold its generic prescription-drug business in 2021 and later added Opill, a non-prescription contraceptive pill, through its HRA Pharma purchase.

Products and services

  • Store-brand OTC (pain, allergy, cough/cold)
  • Infant formula/nutrition
  • Oral care/other consumer health

Customers

  • Mass retailers (Walmart, CVS, Walgreens)
  • Grocery/pharmacy chains

Where it sits in the supply chain

  • Consumer health manufacturing
  • Store-brand OTC drug production
  • Retailer private-label supply

What could go right

  • Retailer private-label share gains vs branded OTC
  • Infant formula capacity recovery

What could go wrong

  • Retailer price/margin pressure
  • Manufacturing/quality regulatory risk (past recalls)

Moat: narrow (scale, cost advantage, regulatory licence). Scale manufacturing and FDA-registered facilities are costly barriers for smaller store-brand suppliers.

Headquarters: Dublin, Ireland · Founded: 1887 · Employees: 8,100

Named competitors

Perrigo at a glance

Size Perrigo (PRGO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.35B, the 1679th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.94 on 18 Nov 2026.

Performance Over six months the shares gained 51.8%, against -11.5% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue fell 4.5% over the last twelve months (peer median +4.2%); the operating margin is 4.6% (peer median 11.1%).

Valuation It trades at 6.7× forward earnings against a peer median of 26.2× (cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.1 points below its cost of capital (6.8% WACC).

Credit Perrigo has 3 bonds outstanding ($1.77B), rated B+ by the agencies and trading like BB at a weighted spread of 184 bp.

Short interest Short interest is 17.7% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026PRGO 149Peer median 89
Six months, rebased to 100: Perrigo against the median of its 20 peers (local-currency closes).

Perrigo financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$4.09B$4.25B$4.37B$4.66B$4.45B
Revenue growth—-3%-6%+5%—
Gross profit$1.32B$1.50B$1.54B$1.68B$1.46B
EBITDA$617M$682M$644M$642M$512M
Net income-$1.77B-$1.43B-$172M-$12.7M-$141M
Free cash flow$168M$145M$245M$304M$211M
Capital expenditure$72.4M$94.9M$132M$102M$96.4M
Total debt$3.45B$3.82B$3.80B$4.26B$4.32B

Quarterly statements and history in the cockpit →

Perrigo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%000250NAMSRGC001330108021623696PBH603858ALM301301APLLTD600867600267IDYA214450BIOA-BH02688428PRGO6-month return →1-month return →
Up and to the right = strong over both horizons. Perrigo is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%25×50×75×001330108021623696PBHALM301301600267214450BIOA-BH02688428PRGORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Perrigo is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%0013301080PBH603858APLLTD214450BIOA-B688428PRGOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Perrigo is the large dot.

Perrigo competitors and peer comparison

Head to head with its named competitors (PRGO vs KVUE vs RKT.L vs CHD)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Perrigo PRGO$2.35B+52%-4%5%6.7×14.1%
Kenvue KVUEn/a+12%n/an/an/an/a
Reckitt Benckiser RKT.L$47.5B+22%-2%28%16.7×2.1%
Church & Dwight CHD$26.4B+16%+2%18%28.1×7.7%
Haleon HLN.L$39.6B0%+1%23%16.4×5.2%

How Perrigo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Perrigo against its 20 peers (data as of 18 Nov 2026)
MeasurePRGOPeer medianRank in peer set
1-month return+4.8%-5.5%2nd highest of 21
6-month return+51.8%-11.5%2nd highest of 21
Distance from 52-week high-0.8%-33.1%highest of 21
Revenue growth (TTM)-4.5%+4.2%9th lowest of 20
Operating margin4.6%11.1%7th lowest of 19
Forward P/E6.7×26.2×cheapest of 15
Growth the price implies (Req g, 7 yrs)14.1%3.3%6th most demanding of 15
Growth delivered (Del g)+0.8%+11.1%4th lowest of 15
Hurdle (Req g minus delivered)+13.3 pp-0.5 pp5th most demanding of 15
ROIC minus cost of capital-4.1 pp-1.3 pp5th lowest of 15
EV / EBITDA8.7×13.7×cheapest of 6
Net debt / EBITDA4.9×-0.6×2nd most indebted of 7
Bond spread184 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%85.7×-10.9%+344.2%

Perrigo bonds and credit

Perrigo has 3 bonds outstanding with $1.77B face value. The agencies rate it B+; its bonds trade like BB. Weighted yield 6.75%, a spread of 184 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Perrigo's main competitors?
Named competitors: Kenvue (KVUE), Reckitt Benckiser (RKT.L), Church & Dwight (CHD), Haleon (HLN.L). The cockpit's measured peer set (industry) also includes Sam Chun Dang Pharm (000250.KS), NewAmsterdam Pharma (NAMS), Regencell Bioscience (RGC), HUTCHMED (China) (0013.HK), Acrobiosystems (301080.SZ), Keymed Biosciences (2162.HK).
Is Perrigo expensive compared with its peers?
On forward p/e it trades at 6.7× against a peer median of 26.2×, cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Perrigo stock performed?
Over six months to 18 Nov 2026 the shares returned +51.8% against -11.5% for the median peer; over one year +24.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.